Images in Haematology
Acquired haemophilia A after alemtuzumab treatment of multiple sclerosis
Huguette S. Brink,
Huguette S. Brink
Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands
Search for more papers by this author Wibe Moll,
Wibe Moll
Department of Neurology, Maasstad Hospital, Rotterdam, The Netherlands
Search for more papers by this author Yorick Sandberg,
Corresponding Author
Yorick Sandberg
Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands
Correspondence: Yorick Sandberg, MD, PhD, Department of Internal Medicine, Maasstad Hospital, Maasstadweg 21, 3079 DZ Rotterdam, The Netherlands.
E-mail: [email protected]
Search for more papers by this author
Huguette S. Brink,
Huguette S. Brink
Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands
Search for more papers by this author Wibe Moll,
Wibe Moll
Department of Neurology, Maasstad Hospital, Rotterdam, The Netherlands
Search for more papers by this author Yorick Sandberg,
Corresponding Author
Yorick Sandberg
Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands
Correspondence: Yorick Sandberg, MD, PhD, Department of Internal Medicine, Maasstad Hospital, Maasstadweg 21, 3079 DZ Rotterdam, The Netherlands.
E-mail: [email protected]
Search for more papers by this author
First published: 16 April 2020
No abstract is available for this article.
Conflicts of interest
The authors declare no conflicts of interest.
Reference
- 1Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015; 86: 208–15.
